Armata Pharmaceuticals (ARMP)
(Delayed Data from AMEX)
$2.57 USD
-0.14 (-5.17%)
Updated Aug 5, 2025 03:19 PM ET
After-Market: $2.57 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ARMP 2.57 -0.14(-5.17%)
Will ARMP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ARMP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARMP
ARMP Soars 72% in a Month Following Infectious Disease Study Success
Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates
ARMP: What are Zacks experts saying now?
Zacks Private Portfolio Services
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates
New Strong Sell Stocks for May 8th
Other News for ARMP
Armata Pharmaceuticals Elects Board Members at Annual Meeting
Innoviva: A Riddle Wrapped In A Mystery Inside An Enigma
Armata Pharmaceuticals (ARMP) Experiences Massive Surge in Interest | ARMP Stock News
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today